Raynaud's Disease

Raynaud's phenomenon (RP) is an exaggerated vasospastic response to cold or emotional stress causing episodic digital ischemia with characteristic triphasic color changes (white → blue → red). [1-2] It affects 3–5% of the general population, with a strong female predominance (F:M ratio ~4:1). [3-4] The critical clinical task is distinguishing primary RP (idiopathic, benign) from secondary RP (associated with underlying disease, particularly connective tissue diseases). [1][5]

The following NEJM algorithm outlines the diagnostic and nondrug management approach:

• Triphasic color change: Ask specifically about well-demarcated pallor (white), cyanosis (blue), and rubor (red) of digits — at least biphasic change (white + blue) is needed for diagnosis [1]
• Triggers: Cold exposure (>80% of cases), emotional stress, rapid temperature shifts (e.g., entering air-conditioned spaces) [1-2]
• Timing and duration: Typical episode lasts ~15–20 minutes after rewarming; ask about frequency, seasonality, and progression over time [1][6]
• Digit involvement: Which fingers/toes? Symmetric vs. asymmetric? Thumb involvement? (Thumb is generally spared in primary RP) [1]
• Associated symptoms: Numbness, tingling, pain during attacks; stinging/throbbing during reperfusion [7]
• Ischemic complications: Digital ulcers, pitting scars, gangrene (strongly suggest secondary RP) [4][8]
• Connective tissue disease symptoms: Arthralgia, skin tightening, dysphagia, dry eyes/mouth, rash, myalgia, fever [5]
• Occupational exposure: Vibratory tools (hand-arm vibration syndrome), repetitive hand trauma [5][8]
• Age of onset: Primary RP typically 15–30 years; secondary RP usually >30–40 years [1][9]

• Digital ulceration, pitting scars, or gangrene — indicates severe ischemia and secondary RP [4][8]
• Acute persistent digital ischemia (prolonged pallor/cyanosis not resolving with rewarming) — constitutes an ischemic crisis requiring urgent intervention [5]
• Asymmetric attacks or involvement of a single digit — raises concern for embolic or structural vascular disease [5]
• Late onset (>40 years) with no prior history — consider secondary causes including malignancy (tumor screening warranted if B symptoms present) [3][5]
• New onset in childhood — rare and points to secondary origin [3]
• Signs of connective tissue disease: Sclerodactyly, skin thickening, telangiectasias, calcinosis, pulmonary hypertension symptoms [1][5]
• Abnormal nailfold capillaries — highly predictive of progression to systemic sclerosis [10-11]

Medications that can trigger/worsen RP (avoid or reassess)

• Beta-blockers (nonselective > selective)
• Ergot alkaloids and triptans (migraine drugs)
• Sympathomimetics, amphetamines, ADHD medications
• Chemotherapeutics (bleomycin, cisplatin, vinblastine)
• Clonidine, cocaine, decongestants
• Caffeine (evidence not solid but commonly listed) [1-2][8]

First-line treatment: Dihydropyridine calcium channel blockers [5][10][12]

• Nifedipine SR 30 mg/day (titrate up; maintenance can exceed 60 mg/day) or amlodipine 5 mg/day
• Cochrane review: ~1.7 fewer attacks/week vs. placebo for primary RP [1][13]
• Side effects: headache, flushing, peripheral edema, hypotension [14]

Second-line options: [1][12][15]

• PDE-5 inhibitors (sildenafil, tadalafil) — especially for refractory RP or digital ulcers
• Topical nitroglycerin 2% ointment (¼–½ inch daily)
• ARBs (losartan 50 mg/day) — some evidence of benefit
• SSRIs (fluoxetine 20 mg/day) — open-label data suggest efficacy
• Prazosin (alpha-1 blocker)

Severe/refractory or digital ulcers: [5][12][15]

• IV iloprost (prostacyclin analogue) — for acute ischemic crisis or refractory ulcers
• Bosentan (endothelin receptor antagonist) — reduces new digital ulcers in scleroderma
• Botulinum toxin injections — emerging evidence for refractory cases
• Aspirin — recommended during acute digital ischemic crisis [5]

Contraindicated/caution: Oral prostaglandins are ineffective for RP. [12] Avoid combining nitrates with PDE-5 inhibitors (hypotension risk).

• Caffeine: Commonly recommended to limit, though evidence is not definitive [1][8]
• Alcohol: Limit intake; while acutely vasodilatory, chronic use and rebound vasoconstriction may worsen symptoms [16]
• Smoking cessation: Critically important — smoking reduces digital blood flow and worsens vascular damage [1][5][8]
• Beetroot juice: One study showed improved peripheral blood flow, endothelial function, and anti-inflammatory status in RP patients following nitrate-rich beetroot supplementation, though this is preliminary [17]
• Hydration: Maintain adequate hydration to support peripheral perfusion
• Omega-3 fatty acids: Sometimes recommended for anti-inflammatory properties, though evidence specific to RP is limited

• Musculoskeletal: Arthralgia, arthritis, myalgia (connective tissue disease)
• Dermatologic: Skin tightening/thickening, telangiectasias, calcinosis, rash (malar, discoid), photosensitivity
• GI: Dysphagia, reflux, bloating (scleroderma esophageal dysmotility)
• Pulmonary: Dyspnea on exertion, dry cough (ILD, pulmonary hypertension)
• Ophthalmologic/Oral: Dry eyes, dry mouth (Sjögren syndrome)
• Constitutional: Fever, weight loss, fatigue (CTD or malignancy)
• Neurologic: Carpal tunnel symptoms, neuropathy
• Vascular: Livedo reticularis, claudication [5][18]

• Family history: 30–50% of patients with primary RP have a first-degree relative with the condition, suggesting genetic susceptibility [1][9]
• Family history of autoimmune disease: Scleroderma, SLE, Sjögren syndrome, rheumatoid arthritis
• Occupational history: Vibratory tool use, cold workplace exposure, repetitive hand trauma [5]
• Social history: Smoking status (critical), recreational drug use (cocaine, amphetamines)
• Medication reconciliation: Confirm all current medications including OTC decongestants, supplements, and migraine treatments [1]

• Female sex (prevalence 2–20% in women vs. 1–12% in men) [2][9]
• Cold climate (geographically variable prevalence) [9]
• Family history of RP or autoimmune disease [1][9]
• Smoking [5][8]
• Occupational vibration exposure (hand-arm vibration syndrome) [5]
• Connective tissue disease (>90% of systemic sclerosis patients have RP) [9]
• Positive ANA or disease-specific autoantibodies (anticentromere, anti-Scl-70) [5][8]
• Abnormal nailfold capillaroscopy [10-11]
• Medications: Beta-blockers, ergotamines, chemotherapy agents [2]
• Hematologic disorders: Polycythemia vera, cryoglobulinemia, cold agglutinin disease [15-16]
• Recent data suggest RP is associated with increased cardiovascular disease and VTE risk independent of traditional risk factors [19]

• Acrocyanosis: Persistent (not episodic) symmetric cyanosis of hands/feet; no pallor phase; benign [15]
• Pernio (chilblains): Inflammatory lesions (erythematous/violaceous papules/nodules) after cold/damp exposure; distinct from vasospasm [15]
• Peripheral arterial disease: Asymmetric, associated with diminished pulses, claudication; older patients with atherosclerotic risk factors
• Thoracic outlet syndrome: Positional symptoms, unilateral, provoked by arm elevation [5]
• Carpal tunnel syndrome: Numbness/tingling in median nerve distribution; may coexist
• Achenbach syndrome: Spontaneous venous hemorrhage of digits; self-limiting, often mistaken for RP [15]
• Complex regional pain syndrome: Pain, swelling, color/temperature changes; usually post-traumatic [15]
• Small fiber neuropathy with vasomotor symptoms [15]
• Embolic disease: Acute unilateral digital ischemia; consider cardiac source, proximal aneurysm
• Cryoglobulinemia / cold agglutinin disease: Hematologic causes of cold-induced digital ischemia
• Erythromelalgia: Episodic burning pain with erythema and warmth (opposite of RP)
• Buerger disease (thromboangiitis obliterans): Young male smokers with distal extremity ischemia

• Connective tissue disease: Systemic sclerosis, SLE, Sjögren syndrome, rheumatoid arthritis, dermatomyositis, mixed CTD [1][4]
• Hypothyroidism: Endocrine cause of secondary RP [3]
• Hematologic disorders: Polycythemia, cryoglobulinemia, paraproteinemia [3]
• Prior digital ulcers or amputations
• Carpal tunnel syndrome (may coexist or mimic)
• Atherosclerotic disease / PAD
• Previous frostbite or hand trauma
• Malignancy (paraneoplastic RP, especially with late-onset) [3]
• Pulmonary hypertension [20]

• Vital signs: Blood pressure in both arms (asymmetry suggests vascular pathology); heart rate
• Hands/feet: Inspect for color changes, digital pitting scars, ulcers, gangrene, calcinosis, sclerodactyly, skin thickening [1][8]
• Nailfold capillaroscopy: Performed with ophthalmoscope or dermatoscope at nail base with drop of oil — look for dilated capillary loops, avascular areas, hemorrhages (scleroderma pattern) [1][10-11]
• Allen test: Assess radial and ulnar artery patency
• Peripheral pulses: Radial, ulnar, dorsalis pedis, posterior tibial — diminished pulses suggest structural vascular disease
• Skin exam: Telangiectasias, malar rash, livedo reticularis, skin tightening, Raynaud-related changes on ears/nose/nipples [6][21]
• Musculoskeletal: Joint swelling, synovitis, tendon friction rubs (scleroderma)
• Thoracic outlet maneuvers: Adson test, costoclavicular maneuver if positional symptoms [5]
• Oral exam: Dry mucous membranes, microstomia (scleroderma)

Initial workup (to distinguish primary from secondary RP): [1][5][16]

• ANA — negative or low-titer (≤1:40) supports primary RP; positive warrants further workup
• Anti-centromere antibody — associated with limited scleroderma (CREST)
• Anti-Scl-70 (anti-topoisomerase I) — associated with diffuse scleroderma
• Anti-RNP — mixed connective tissue disease
• ESR / CRP — elevated suggests secondary cause (though normal ESR no longer required to diagnose primary RP) [1]
• CBC — polycythemia, thrombocytosis, anemia
• Comprehensive metabolic panel — renal function (scleroderma renal crisis)
• TSH — hypothyroidism as secondary cause
• Rheumatoid factor
• Complement levels (C3, C4) — if SLE suspected
• Cryoglobulins — if hematologic cause suspected
• Urinalysis — proteinuria (renal involvement in CTD)

A connective tissue disease developed in only 2% of patients who were seronegative for ANA and RF, versus ~15–20% of those with positive autoantibodies or abnormal capillaroscopy. [5]

• Nailfold capillaroscopy: First-line and most important imaging tool — gold standard for microvascular assessment; abnormal patterns (giant capillaries, hemorrhages, avascular areas) are highly predictive of SSc [1][10-11]
• Arterial Doppler / duplex ultrasound: If concern for proximal arterial occlusion, thoracic outlet syndrome, or embolic disease
• CT angiography or MR angiography: For suspected large-vessel disease or thoracic outlet syndrome
• Chest X-ray / CT chest: If pulmonary symptoms suggest ILD or pulmonary hypertension in secondary RP
• Echocardiography: If pulmonary hypertension suspected (elevated RVSP)
• Imaging is generally unnecessary for straightforward primary RP in young patients with normal exam and negative serologies [1][5]

• Nailfold capillaroscopy: Key risk-stratification tool; scleroderma pattern predicts CTD transition [10-11]
• Cold stimulation test: Hands immersed in ice water; recovery time >20 minutes suggests RP [16]
• Raynaud's Condition Score (RCS): Patient-reported 0–10 scale assessing daily difficulty; used to guide treatment escalation [1]
• Laser Doppler flowmetry / thermography: Research tools for quantifying digital perfusion; not widely used clinically [22]
• Digital plethysmography: Assesses digital artery pressures and waveforms
• Botulinum toxin injection: Both diagnostic (response confirms vasospastic component) and therapeutic in refractory cases [15]

• ECG is not routinely indicated for isolated primary RP
• In secondary RP with systemic sclerosis, ECG may reveal:
  • Conduction abnormalities (bundle branch blocks, AV blocks)
  • Arrhythmias (atrial and ventricular)
  • ST-T wave changes during cold-induced "cardiac Raynaud's" (transient myocardial ischemia) [23-24]
• Cold-induced segmental myocardial dysfunction has been demonstrated in SSc patients with long-standing RP (>5 years), even with normal coronary arteries [24-25]
• Consider ECG if chest pain, palpitations, or syncope in the setting of secondary RP
• RP patients have higher rates of ischemic heart disease (22.9% vs. 19.5%) and heart failure (19.2% vs. 14.5%) compared to matched controls [20]

Primary RP (80–90% of cases): [9]

• Onset age 15–30, female predominance, symmetric, thumb spared
• Mild attacks, no digital ulcers, normal nailfold capillaries, negative/low-titer ANA
• Benign course; however, ~12.6% may develop a secondary cause over time (almost all CTD) [5]

Secondary RP (10–20% of cases)

• Onset >30–40 years, more severe/painful attacks, asymmetric involvement possible
• Digital ulcers, pitting scars, gangrene may occur [4][8]
• Most commonly associated with systemic sclerosis (>90% of SSc patients have RP) [9]
• Other associations: SLE, Sjögren, RA, dermatomyositis, MCTD, hematologic disorders [6]

Complications: Digital ulceration, critical digital ischemia, tissue necrosis, amputation (rare, almost exclusively secondary RP), and increased cardiovascular/VTE risk. [14][19]

All patients — nonpharmacologic (foundation of therapy): [1][5][8]

• Cold avoidance: layered clothing, gloves, hats, heated gloves/footwear, chemical hand warmers
• Avoid rapid temperature shifts
• Smoking cessation (strongly recommended)
• Stress reduction techniques
• Avoid offending medications (beta-blockers, ergotamines, sympathomimetics)
• Regular exercise to improve peripheral circulation

Pharmacologic — stepwise escalation: [1][5][12]

Acute digital ischemic crisis: Immediate rewarming, vasodilator therapy (nifedipine or IV iloprost), aspirin, and urgent evaluation for underlying cause. [5] Early intervention is key before irreversible tissue injury.

Discharge criteria (majority of RP presentations)

• Primary RP with mild-moderate symptoms responding to rewarming
• No digital ulcers, gangrene, or signs of critical ischemia
• Able to follow up with PCP or rheumatology
• Appropriate prescriptions and lifestyle counseling provided

Observation / Admission criteria

• Acute digital ischemic crisis with persistent ischemia despite rewarming and oral vasodilators [5]
• Digital gangrene or threatened tissue loss requiring IV prostanoid therapy
• Severe pain uncontrolled with oral medications
• New diagnosis of secondary RP with concerning systemic features (e.g., scleroderma renal crisis, pulmonary hypertension)

Specialist consultation triggers: [10][12]

• Rheumatology: Suspected secondary RP, positive autoantibodies, abnormal capillaroscopy, digital ulcers
• Vascular surgery: Refractory ischemia, consideration for sympathectomy, suspected large-vessel disease
• Hand surgery: Digital ulcers requiring debridement or threatened amputation
• Cardiology: Suspected pulmonary hypertension or cardiac involvement
• Pulmonology: ILD screening in SSc-associated RP

Follow-up timing

• Primary RP: PCP follow-up in 2–4 weeks if starting medication; annual reassessment for evolution to secondary RP [3]
• Secondary RP: Rheumatology follow-up within 2–4 weeks; ongoing monitoring for organ involvement
• Patients with positive ANA or abnormal capillaroscopy but no definite CTD: ~15–20% will develop a defined CTD, usually within 2 years — close surveillance warranted [5]

Return precautions — instruct patients to seek immediate care for:

• Persistent color change (white or blue) in a digit lasting >30 minutes despite rewarming
• New digital ulcers, open sores, or blackened skin on fingertips
• Severe unrelenting pain in digits
• Fever, new joint swelling, skin changes, or difficulty swallowing (suggesting CTD progression)
• Chest pain or shortness of breath

Patient counseling

• RP is a chronic condition; primary RP is generally benign with excellent prognosis
• Lifestyle modifications are the cornerstone and often sufficient for primary RP [1]
• Medication side effects (headache, flushing, edema with CCBs) are common but manageable
• Expected recovery: attacks typically resolve within 15–20 minutes of rewarming [6]
• Long-term specialist care is necessary for patients with risk factors for secondary RP [3]

1. Raynaud’s Phenomenon. — Wigley FM, Flavahan NA. The New England Journal of Medicine. 2016.

2. Vasodilators for Primary Raynaud's Phenomenon. — Su KY, Sharma M, Kim HJ, et al. The Cochrane Database of Systematic Reviews. 2021.

3. Raynaud's Phenomenon: A Vascular Acrosyndrome That Requires Long-Term Care. — Klein-Weigel P, Sander O, Reinhold S, et al. Deutsches Arzteblatt International. 2021.

4. Raynaud's Phenomenon. — Haque A, Hughes M. Clinical Medicine. 2020.

5. Raynaud's Phenomenon. — Wigley FM. The New England Journal of Medicine. 2002.

6. Raynaud phenomenon. — National Library of Medicine (MedlinePlus) 2018.

7. Clinically Relevant Differences Between Primary Raynaud's Phenomenon and Secondary to Connective Tissue Disease. — Di Donato S, Huang S, Pauling JD, et al. Seminars in Arthritis and Rheumatism. 2024.

8. Raynaud's Phenomenon. — Block JA, Sequeira W. Lancet. 2001.

9. Calcium Channel Blockers for Primary and Secondary Raynaud's Phenomenon. — Rirash F, Tingey PC, Harding SE, et al. The Cochrane Database of Systematic Reviews. 2017.

10. Practical Management of Raynaud's Phenomenon - A Primer for Practicing Physicians. — Ramahi A, Hughes M, Khanna D. Current Opinion in Rheumatology. 2022.

11. Causes of Raynaud's Phenomenon and the Predictive Laboratory and Capillaroscopy Features for the Evolution to a Definite Connective Tissue Disease. — Shenavandeh S, Ajri M, Hamidi S. Rheumatology. 2022.

12. Systemic Sclerosis: Evaluation and Treatment. — Frazier W, Goettel C, Chaudhri P. American Family Physician. 2026.

13. Calcium Channel Blockers for Primary Raynaud's Phenomenon. — Ennis H, Hughes M, Anderson ME, Wilkinson J, Herrick AL. The Cochrane Database of Systematic Reviews. 2016.

14. The Diagnosis and Treatment of Raynaud's Phenomenon: A Practical Approach. — Pope JE. Drugs. 2007.

15. Cold Hands or Feet: Is It Raynaud's or Not?. — Kadian-Dodov D. The Medical Clinics of North America. 2023.

16. Cold Stimulation Test. — National Library of Medicine (MedlinePlus) 2021.

17. "Beet" the Cold: Beetroot Juice Supplementation Improves Peripheral Blood Flow, Endothelial Function, and Anti-Inflammatory Status in Individuals With Raynaud's Phenomenon. — Shepherd AI, Costello JT, Bailey SJ, et al. Journal of Applied Physiology. 2019.

18. Raynaud's Phenomenon-an Update on Diagnosis, Classification and Management. — Pauling JD, Hughes M, Pope JE. Clinical Rheumatology. 2019.

19. Raynaud's Phenomenon Is Associated With an Increased Risk of Cardiovascular Disease and Venous Thromboembolism. — Hughes M, Ruaro B, McMahan ZH, et al. Seminars in Arthritis and Rheumatism. 2025.

20. Cardiovascular Disease and Inpatient Complications in Raynaud's Syndrome: Propensity Score Analysis. — Alzahrani T. The American Journal of the Medical Sciences. 2025.

21. The Role of the Dermatologist in Raynaud's Phenomenon: A Clinical Challenge. — Matucci-Cerinic C, Nagaraja V, Prignano F, Kahaleh B, Bellando-Randone S. Journal of the European Academy of Dermatology and Venereology : JEADV. 2018.

22. Raynaud Phenomenon and Microvasculopathy in Systemic Sclerosis: Multi-Modality Imaging for Diagnosis and Evaluation. — Markousis-Mavrogenis G, Bournia VK, Sfikakis PP, Mavrogeni SI. Current Opinion in Rheumatology. 2023.

23. The Cardiac Magnetic Resonance in the Diagnosis of Cardiac Raynaud Phenomenon in a Patient With Systemic Sclerosis: Case Report and Review of Literature. — Quarta S, Galea N, Gigante A, et al. Expert Review of Clinical Immunology. 2015.

24. Cold-Induced Coronary Raynaud's Phenomenon in Patients With Systemic Sclerosis. — Lekakis J, Mavrikakis M, Emmanuel M, et al. Clinical and Experimental Rheumatology. 1998.

25. Left Ventricular Dysfunction Induced by Cold Exposure in Patients With Systemic Sclerosis. — Ellis WW, Baer AN, Robertson RM, Pincus T, Kronenberg MW. The American Journal of Medicine. 1986.